Vocabria and rilpivirine injections are intended for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral medicinal products for the treatment of HIV. Based on the in vitro and clinical drug interaction profile, cabotegravir is not expected to alter concentrations of other antiretroviral medications including protease inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, integrase inhibitors, entry inhibitors or ibalizumab. Coadministration of etravirine and oral cabotegravir increased cabotegravir AUC and Cmax by 1% and 4% and had no effect on Ctau. Etravirine did not significantly change cabotegravir plasma concentration. No dose adjustment of Vocabria is necessary when initiating injections following etravirine use.

Rekambys should not be administered with other antiretroviral medicinal products, except for cabotegravir injection for the treatment of HIV-1 infection. From a drug interaction perspective, there are no limitations on the use of other antiretroviral medicinal products after discontinuing Rekambys.

Because Cabenuva is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). These residual concentrations are not expected to affect the exposures of antiretroviral drugs that are initiated after discontinuation of Cabenuva. Based on drug interaction study results, etravirine can be given after discontinuation of cabotegravir without a dose adjustment. Coadministration of etravirine (200 mg twice daily) and oral cabotegravir (30 mg once daily) was studied in 12 subjects. Cabotegravir Cmax and AUC increased by 4% and 1%, and there was no change in Ctau.

Coadministration of oral cabotegravir (30 mg once daily) and etravirine (200 mg twice daily) was studied in 12 subjects. Cabotegravir and etravirine in combination for 14 days were well tolerated and there was no significant effect of etravirine on cabotegravir pharmacokinetics (AUC and Cmax increased by 1% and 4%; no change in C24). Etravirine pharmacokinetics parameters were in the range of historical values reported for etravirine alone in healthy subjects. These results indicate that no dose adjustment of cabotegravir is required when coadministered with etravirine.